3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
5
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Colorectal Neoplasms
59
Pancreatic Neoplasms
33
Colonic Neoplasms
31
Rectal Neoplasms
30
Stomach Neoplasms
22
Neoplasm Metastasis
19
Carcinoma, Non-Small-Cell Lung
19
Neoplasms
16
Unspecified Adult Solid Tumor, Protocol Specific
15
Esophageal Neoplasms
12
Ovarian Neoplasms
8
Gallbladder Neoplasms
7
Appendiceal Neoplasms
7
Melanoma
6
Lymphoma, Large B-Cell, Diffuse
6
Lung Neoplasms
6
Carcinoma, Renal Cell
6
Breast Neoplasms
6
Bile Duct Neoplasms
6
Peritoneal Neoplasms
5
Liver Neoplasms
5
Gastrointestinal Neoplasms
5
Carcinoma, Hepatocellular
5
Adenocarcinoma
5
Triple Negative Breast Neoplasms
4
Recurrence
4
Fallopian Tube Neoplasms
4
Esophageal Squamous Cell Carcinoma
4
Carcinoma, Pancreatic Ductal
4
Squamous Cell Carcinoma of Head and Neck
3
Interventions
pembrolizumab
26
Gemcitabine
20
Cisplatin
12
Nivolumab
11
Carboplatin
8
Paclitaxel
7
Docetaxel
7
atezolizumab
6
durvalumab
5
Radiotherapy
5
fludarabine
4
enfortumab vedotin
4
Ipilimumab
4
Cyclophosphamide
4
Vorinostat
3
Magnetic Resonance Spectroscopy
3
Fluorouracil
3
Filgrastim
3
Doxorubicin
3
zimberelimab
2
vocimagene amiretrorepvec
2
tremelimumab
2
romidepsin
2
poly ICLC
2
infigratinib
2
erdafitinib
2
cc-486
2
belinostat
2
avelumab
2
amminedichloro(2-methylpyridine)platinum(II)
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Urinary Bladder Neoplasms
×
Oxaliplatin
×
Clear all
NCT05891171
2026-06-05
ARC-25
Arcus Biosciences, Inc.
Phase 1
Active not recruiting
40 enrolled